> DSM-Firmenich has exclusive rights to market bemotrizinol in the U.S. for 18 months. It will be sold under the brand name Parsol Shield.
I also imagine that it’s not really worth doing just to get a specific brand in terms of cost.
An 18-month exclusive period is annoying but not the end of the world.